A Phase 3 interventional study of Ticagrelor 90 mg and Ticagrelor 60 mg in Myocardial Infarction, sponsored by Collegium Medicum w Bydgoszczy. Completed at 1 site in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-21.
Sponsored by Collegium Medicum w Bydgoszczy · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing ticagrelor in Myocardial Infarction — 3 open to participants now, 3 under way, 1 of them phase 3. Ticagrelor · Myocardial Infarction.
Among the 36 studies testing ticagrelor in Myocardial Infarction, this one is the 28th largest by enrollment, is one of 6 that started in 2017, is one of 11 in phase 3, and was the 22nd registered.
2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.
Browse Myocardial Infarction studies →3 of the 36 studies testing ticagrelor in Myocardial Infarction are open now, in 7 countries. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Ireland, Latvia, Norway and 2 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 55+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 255 Myocardial Infarction studies recruiting now, 172 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 16 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 150 across 1,314 interventional studies indexed under Myocardial Infarction.
Median enrollment 132 across the 36 interventional studies. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
Collegium Medicum w Bydgoszczy is the lead sponsor of 26 studies on the registry; 4 are open to participants now.
Collegium Medicum w Bydgoszczy has 4 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
1 of the studies testing ticagrelor in Myocardial Infarction that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing ticagrelor in Myocardial Infarction, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The ELECTRA pilot study is a randomized, open-label, pharmacokinetic and pharmacodynamic trial designed to evaluate the effect of ticagrelor maintenance dose reduction on platelet inhibition in stable patients who recently underwent acute myocardial infarction and were treated with percutaneous coronary intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention.
Drug: Ticagrelor 90 mg
Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days.
Drug: Ticagrelor 90 mg · Drug: Ticagrelor 60 mg
Ticagrelor 90 mg twice daily
Also known as: Brilique 90 mg
Ticagrelor 60 mg daily
Also known as: Brilique 60 mg
Platelet Reactivity Assessed with the VASP assay
Platelet inhibition evaluated with the VASP assay 45 days after myocardial infarction.
Time frame: 45 days
Platelet Reactivity Assessed with Multiple Electrode Aggregometry
Platelet inhibition evaluated with Multiple Electrode Aggregometry 45 days after myocardial infarction.
Time frame: 45 days
Number of Patients With High Platelet Reactivity according to the VASP assay
Number of Patients With High Platelet Reactivity according to the VASP assay 45 days after myocardial infarction.
Time frame: 45 days
Number of Patients With High Platelet Reactivity according to Multiple Electrode Aggregometry
Percentage of Patients With High Platelet Reactivity according to Multiple Electrode Aggregometry 45 days after myocardial infarction.
Time frame: 45 days
Plasma concentration of Ticagrelor
Evaluation of ticagrelor plasma concentration 45 days after myocardial infarction.
Time frame: 45 days
Plasma concentration of AR-C124910XX
Evaluation of ticagrelor active metabolite plasma concentration 45 days after myocardial infarction.
Time frame: 45 days
Plan to share: Undecided
Ran from Aug 2017 to primary completion in Feb 2018, 6 months.
Of 33 non-industry phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 73. This study's 6 months is below that.
Counting every sponsor, half of 57 studies reached it within 43 months; a quarter within 30 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor
Collegium Medicum w Bydgoszczy